In people with atherosclerotic cardiovascular disease & overweight or obesity Semaglutide ⬇️ MACE & composite heart failure endpoints vs placebo in those with & without clinical HF Pre-specified analysis of the SELECT trial thelancet.com/journals/lance…

The economic impact of obesity People with chronic kidney disease or cardiovascular disease incurred particularly high costs Primary care costs are a fraction of total costs! dom-pubs.onlinelibrary.wiley.com/doi/full/10.11…

Dear Friends If you are attending EASD in Madrid - please do register for our 60th Anniversary celebrations easd.org/index.html

Interesting guideline from European Society of Cardiology #ESCCongress #ESCCongress2024 ➡️ Obesity & CVD Spoke on this topic last year & fairly aligned- guidelines have to (largely) go by strongest ‘current’ evidence base…things will develop! 2 choice illustrations for me Dr. Deepak L. Bhatt Prof Kamlesh Khunti

Ready to review all hings Finerenone and HF! Aiditorium almost full! European Society of Cardiology #ESCCongress Muthu Vaduganathan

For review AFTER the session only 😇 Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine nejm.org/doi/full/10.10… #ESCCongress #ESCCongress2024 Prof Kamlesh Khunti European Society of Cardiology SABOURETCardiologist EASD American College of Cardiology

Finerenone in Heart Failure FINEARTS-HF 🔸EF >/= 40% 🔹Finerenone 20mg or 40mg vs placebo 🔸1ry endpoint composite worsening HF event + CV death 🔹Finerenone ⬇️ 1ry endpoint - HF event driven HR 0.84 (CI 0.74-0.95) 🔸ARR 3.3/100 patient years 🔹numerical CV death ⬇️🤷🏽‍♂️

Have you met Patrick Holmes who sits on our faculty? He has been a GP Partner at St George’s Medical Practice, Darlington for 25 years. And he'll be speaking at our webinar on CKD in October: cvrmuk.com/events/44/card… He is also an active participant of GoggleDocs

Approximately 1 in 5 people discontinued GLP-1RA therapy within the first 12 months and only half were adherent. Lower socioeconomic status & higher comorbidity burden were associated with higher risk of discontinuing GLP-1RA treatment Danish data dom-pubs.onlinelibrary.wiley.com/doi/epdf/10.11…

In people with type 2 diabetes aged 40-69 years SGLT-2 inhibitors (compared with DPP-4 inhibitors) associated with 35% lower risk of dementia The BMJ bmj.com/content/386/bm…

❗️Howdy folks❗️ 👇Check out our latest video👇 Semaglutide... The Good, the Bad and the Ugly youtu.be/HXi7-jEPTmI?si… via YouTube

ESC ❤️ Residual risk - TG - IPE REDUCE-IT showed a 25% ⤵️ in 5 point MACE in 👥 with 👉🏼 CV dx or DM >50yo with 1 risk factor 👉🏼 TG > 1.7 🔸 CV benefit was independent of LDL 🔸 IPE Also showed a ⤵️ in recurrent & total events #ESCCongress2024 #ESCCongress European Society of Cardiology

GLP-1 receptor agonists associated with a significantly lower incidence of glaucoma, ocular hypertension, a Compared to metformin in people with type 2 diabetes. sciencedirect.com/science/articl…

SGLT2i associated with better preservation of renal function compared with GLP-1RA in T2 diabetes Slower decline in eGFR link.springer.com/article/10.100…

GLP-1 RA, in addition to SGLT2i, associated with a significantly lower risk of heart failure hospitalisation sciencedirect.com/science/articl…

Treatment with SGLT2 inhibitors after myocardial infarction in people with T2 diabetes associated with a lower rate of cardiovascular events. SWEDEHEART study thelancet.com/journals/lanep…